June 28, 2013

Lyxumia® is first diabetes therapy of its class approved in Japan for use in combination with basal insulin

First once-daily prandial GLP-1 receptor agonist offering a new treatment option for Japanese people living with type 2 diabetes

 

Lyxumia® is first diabetes therapy of its class approved in Japan for use in combination with basal insulin
First once-daily prandial GLP-1 receptor agonist offering a new treatment option for Japanese people living with type 2 diabetes

Paris, France – June 28, 2013 – Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the manufacturing and distribution of Lyxumia® (lixisenatide) for the treatment of type 2 diabetes. Lyxumia, the first once- daily prandial GLP-1 receptor agonist (RA), is also the first GLP-1 RA approved in Japan for use in combination with basal insulin. Lyxumia is indicated for patients with type 2 diabetes mellitus when the following do not provide adequate glycemic control: diet and exercise and sulfonylureas (with and without biguanides) or diet and exercise and soluble prolonged-acting or intermediate-acting insulin (with and without sulfonylureas).